CD34+ HSC Humanized Mouse Models

CD34-positive humanized mouse models are immunodeficient mice reconstituted with human hematopoietic stem and progenitor cells. Rather than transferring mature immune cells, the platform transfers the precursors from which they develop: CD34-positive cells home to the bone marrow niche, engraft, and initiate human hematopoiesis in the host. Over subsequent weeks human leukocytes populate peripheral blood and secondary lymphoid tissues.

The consequence is a multilineage human immune compartment rather than a T-cell dominated one. CD34-positive progenitors give rise to T lymphocytes, B lymphocytes, natural killer cells, monocytes and macrophages, dendritic cells, and granulocytes, which makes the platform suitable for mechanisms that peripheral blood reconstitution cannot address.

Altogen Labs conducts CD34-positive humanized studies in an IACUC-regulated facility using commercially obtained cord blood derived cells from suppliers maintaining donor eligibility documentation. Reconstitution is verified against defined eligibility criteria before animals enter study. To discuss timelines and platform fit, request a quote.

Reconstitution timeline

The trade-off against peripheral blood reconstitution is lead time. Following engraftment, the first weeks are occupied by homing and establishment in the marrow niche. Human CD45-positive cells become detectable in peripheral blood thereafter, followed by expansion of T and B cell populations, and multilineage reconstitution stabilizes over a period of several months rather than weeks.

Study-eligible immune profiles are therefore reached on a timescale that must be built into program planning from the outset. Animals are prepared in advance of the study rather than commissioned when the compound is ready, and a program that treats humanization as a short preparatory step will find the schedule dominated by it.

Eligibility criteria

Reconstitution is not assumed from the procedure having been performed. Study initiation requires human CD45-positive cells in peripheral blood above a defined threshold, a detectable CD3-positive T-cell population, a balanced CD4 to CD8 distribution, and absence of clinical distress. Animals not meeting these criteria are excluded before randomization rather than carried into the study and accounted for afterward, since a poorly reconstituted animal contributes variance without contributing information.

Applications

The platform supports immune checkpoint inhibitor evaluation, bispecific T-cell engager testing, CAR-T and engineered cell persistence studies, natural killer cell therapy, cytokine and immune agonist biology, and combination immunotherapy optimization. Because study durations are longer, it is also the appropriate platform where durability of response rather than initial activity is the question.

The recognized limitation is that human myeloid, natural killer, and stromal biology are not fully reproduced. Conventional dendritic cells and tissue macrophages remain underrepresented relative to a human immune system, and this should be stated when interpreting a mechanism that depends on them.

Study design and endpoints

Tumor configurations include subcutaneous, orthotopic, metastatic and disseminated, and systemic hematologic models. Randomization is stratified by reconstitution level as well as by baseline tumor volume, since immune status is a determinant of response and unbalanced groups would confound the treatment comparison.

Primary endpoints are tumor volume, tumor growth inhibition, and survival. Secondary endpoints include flow cytometric immune profiling covering human CD45, CD3, CD4, CD8, CD19, CD56, CD14, and activation and checkpoint markers; cytokine quantification including interferon gamma, interleukin 2, tumor necrosis factor alpha, and interleukin 6; and immunohistochemical assessment of CD8-positive infiltration, CD4-positive density, tumor architecture, and immune spatial distribution.

Applied examples

Checkpoint inhibitor evaluation. Tumor-bearing humanized animals are randomized to vehicle or anti-PD-1 therapy, with tumor volume and growth inhibition measured alongside CD8-positive infiltration by immunohistochemistry and interferon gamma in tumor and plasma, so reduced growth is linked to increased effector infiltration rather than reported in isolation.

Durable response. A candidate immunotherapy is assessed over an extended treatment and follow-up period, with tumor control and immune population composition tracked beyond the point at which a peripheral blood model would have been terminated.

Combination sequencing. An immune agonist and a checkpoint antibody are administered concurrently in one arm and sequentially in another, with immune profiling used to establish which schedule produces greater effector expansion.

Variability, controls, and oversight

Donor-to-donor differences in reconstitution efficiency are an intrinsic feature of the platform and are managed through eligibility thresholds, stratified randomization, and cohort sizing that accounts for the additional variance rather than assuming murine-model uniformity. All procedures are conducted under active IACUC protocols, with controlled housing appropriate to severely immunodeficient animals and defined sampling schedules. Human cells are commercially obtained with donor eligibility documentation maintained by the supplier. GLP standards are applied where a study is formally designated as GLP.

Send mechanism, required study duration, and tumor model, or request a quote.